Why Research Peptide Companies Are Suddenly Shutting Down скачать в хорошем качестве

Why Research Peptide Companies Are Suddenly Shutting Down

Why Peptide Sciences Shut Down: The 3 Medication Supply Chains & What Happens Next The episode explains the sudden shutdown of Peptide Sciences and argues it may signal broader enforcement against research peptide vendors. It breaks down how medications reach patients through three parallel systems: FDA-approved retail pharmacy drugs, state-regulated compounding pharmacies that prepare patient-specific prescriptions, and research chemical companies selling “for research use only” products with no prescriptions or medical oversight. The host says regulators focus on “intent” when research-only chemicals are widely used and marketed for medical purposes, and notes financial pressure on payment processors can cripple vendors. It also clarifies the FDA’s compounding bulk substance guidance and its Category 1–3 framework, emphasizing Category 2 as a subjective gray zone cited for peptides like BPC-157, while discussing patent and lobbying dynamics. The takeaway is to work with qualified practitioners and use legitimate medical channels. 00:00 Peptide Sciences Shutdown 00:58 How Meds Reach Patients 01:20 Retail Pharmacy System 02:36 Compounding Pharmacies Explained 03:54 Research Chemical Underground 06:08 Why Regulators Crack Down 07:07 Payment Networks Pressure 07:34 FDA Compounding Categories 09:46 Category Two Gray Zone 11:11 Patents and Pharma Incentives 12:03 Patient Safety Takeaways 13:03 Wrap Up and Subscribe DISCLAIMER: This video is for educational and entertainment purposes only and should not be used as replacement for proper and individualized medical advice from your trusted practitioner. I am a medical practitioner and I invite you to consult with me as a patient to further discuss your individual needs, via our website, www.Team360Health.com